Lenalidomide selectively inhibits in vitro growth of the malignant clone in myelodysplastic syndrome (MDS) patients with 5q deletion.

Ижил төстэй зүйлс

• Lenalidomide up-regulates SPARC and inhibits in vitro growth of the malignant clone in myelodysplastic syndrome patients with 5q deletion.
  -н: Pellagatti, A, зэрэг
  Хэвлэсэн: (2006)
• Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.
  -н: Pellagatti, A, зэрэг
  Хэвлэсэн: (2007)
• Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.
  -н: Jädersten, M, зэрэг
  Хэвлэсэн: (2009)
• Del(5q) Myelodysplastic Stem Cells Exhibit Their Clonal Advantage Via Increased Adhesion to the Microenvironment
  -н: Scharenberg, C, зэрэг
  Хэвлэсэн: (2011)
• Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression
  -н: Martin Jädersten, зэрэг
  Хэвлэсэн: (2009-12-01)